作者: Swaroop Revannasiddaiah , Subhash Chandra Joshi , Kailash Chandra Pandey , Madhup Rastogi , Mukesh Sharma
DOI: 10.3978/J.ISSN.2305-5839.2015.11.25
关键词:
摘要: Background: A considerable proportion of non-small cell lung carcinoma (NSCLC) patients are ineligible for radical therapies. Many frail not to tolerate intravenous palliative chemotherapy either. These often receive radiotherapy (RT), or supportive care alone. We intend compare outcomes with RT alone, versus plus oral low dose metronomic cyclophosphamide. Methods: Data was mined from 139 eligible NSCLC patient records. Comparisons were made between 65 treated January 2011 March 2013 (20-30 Gray in 5-10 fractions) 74 April December 2014 cyclophosphamide (50 mg once daily day initiation until at least the disease progression). Response assessed after 1-month post-RT by computed tomography. Patients complete partial response recorded as responders. For determination progression free survival (PFS), would be declared case increase size lesions, development new effusions. The proportions responders compared Fisher exact test, and PFS curves log-rank test. Results: Differences rates statistically insignificant. significantly higher when added comparison treatment alone (mean 3.1 vs . 2.55 months; P=0.0501). Further histological sub-group analysis revealed that enhanced addition limited adenocarcinoma histology (3.5 2.4 P=0.0053), while there no benefit those squamous (2.6 2.6 P=1). At used, instance any measurable hematological toxicity. Conclusions: pulmonary patients, is better than However, offered benefit. studies similar different agents justifiable.